1. Volume 123, Issue 3, Pages 719-727 (September 2002)
Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy 
Robert J. Fontana, Hie-Won L. Hann, Robert P. Perrillo, John M. Vierling, Theresa Wright, Jorge Rakela, Gaya Anschuetz, Randy Davis, Stephen D. Gardner, Nathaniel A. Brown 
Gastroenterology 
Volume 123, Issue 3, Pages (September 2002)
DOI: /gast
Copyright © 2002 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Kaplan-Meier plot of patient survival in the entire cohort (n = 154), NS patients surviving <6 months (n = 25), and SURV patients, which includes patients surviving ≥6 months and those with less than 6 months of follow-up (n = 129). The actuarial 3-year survival in the SURV group was 88% and 73% in the overall group.
Gastroenterology  , DOI: ( /gast )
Copyright © 2002 American Gastroenterological Association Terms and Conditions

3. Fig. 2
Predicted 6-month survival in patients with HBV cirrhosis receiving lamivudine, using the model derived from our data set. Index = 0.5 × bili × creatinine × HBV DNA (0 or 1).
Gastroenterology  , DOI: ( /gast )
Copyright © 2002 American Gastroenterological Association Terms and Conditions

4. Fig. 3
(A) Proportion of NS and SURV patients who became HBV DNA negative during the first 24 weeks of lamivudine treatment. (B) Median serum bilirubin levels in NS and SURV patients through week 24 of lamivudine treatment. (C) Median serum albumin levels in NS and SURV patients through week 24 of lamivudine treatment. Error bars for B and C represent 95% confidence intervals.
Gastroenterology  , DOI: ( /gast )
Copyright © 2002 American Gastroenterological Association Terms and Conditions